Erste Group Bank Has Positive Opinion of BMY FY2027 Earnings

Key Points

• Erste Group Bank raised its FY2027 EPS estimate for Bristol Myers Squibb to $6.56 from $6.53, matching the current analyst consensus.
• Bristol Myers Squibb’s latest quarterly results exceeded expectations, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year. The company guided to FY2026 EPS of $6.75–$7.00.
• Analyst sentiment is generally positive, with a “Moderate Buy” consensus and an average price target of $64.88, while the stock offers a 4.0% dividend yield. Investors remain focused on pipeline progress and risks from generic competition affecting older products.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Research analysts at Erste Group Bank raised their FY2027 earnings per share (EPS) estimates for Bristol Myers Squibb in a report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings of $6.56 per share for the year, up from their prior estimate of $6.53. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.56 per share.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

A number of other research analysts also recently weighed in on BMY. The Goldman Sachs Group upgraded shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 16th. Citigroup restated a "neutral" rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. TD Cowen initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating for the company. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Finally, BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and an average target price of $64.88.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $63.10 on Friday. The company has a market capitalization of $128.89 billion, a PE ratio of 13.90, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company's fifty day moving average price is $63.31 and its 200 day moving average price is $60.32. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $68.64.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.05% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds have recently made changes to their positions in the company. Altura Wealth Advisors Inc. boosted its stake in Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company's stock worth $856,000 after purchasing an additional 161 shares during the last quarter. Barrett & Company Inc. grew its holdings in shares of Bristol Myers Squibb by 9.2% during the third quarter. Barrett & Company Inc. now owns 5,999 shares of the biopharmaceutical company's stock worth $374,000 after buying an additional 506 shares in the last quarter. Capital City Trust Co. FL raised its position in shares of Bristol Myers Squibb by 0.7% in the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company's stock valued at $1,455,000 after buying an additional 167 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of Bristol Myers Squibb by 4.3% in the third quarter. Sterling Capital Management LLC now owns 229,996 shares of the biopharmaceutical company's stock valued at $14,352,000 after buying an additional 9,542 shares during the last quarter. Finally, XXI Wealth LLC lifted its stake in shares of Bristol Myers Squibb by 87.4% in the third quarter. XXI Wealth LLC now owns 30,096 shares of the biopharmaceutical company's stock worth $1,878,000 after buying an additional 14,039 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Fresh oncology and pulmonary-fibrosis updates, including data headed to the ESMO 2026 Congress and positive Phase 3 results, are reinforcing confidence in BMY’s pipeline and helping support recent share momentum. Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
• Positive Sentiment: Bristol Myers Squibb is launching a national collaboration with IHI to expand access to cancer clinical trials, potentially improving research reach and supporting the company’s long-term oncology strategy. IHI and Bristol Myers Squibb Launch National Collaborative
• Positive Sentiment: Compared with Pfizer, BMY has posted a steadier revenue trajectory, with continuous year-over-year growth across recent quarters. Its dividend also has a more comfortable payout ratio, strengthening the stock’s appeal to income-oriented investors. Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
• Neutral Sentiment: BMY’s upcoming quarterly report is drawing attention. Earlier results benefited from Camzyos and oncology products, while the company’s FY 2026 EPS guidance remains a valuation support; nevertheless, analysts expect year-over-year earnings pressure in the upcoming quarter. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline
• Negative Sentiment: Generic competition across BMY’s older portfolio, particularly as legacy drugs face pricing and market pressures, could weigh on growth. Eliquis remains a key strength, but investors are monitoring concentration and replacement-product risks. Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

Bristol Myers Squibb Company Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.